MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment

Central European Journal of Medicine - Tập 8 - Trang 679-684 - 2013
Antoaneta Gateva1, Zdravko Kamenov1, Adelina Tsakova2
1Clinic of Endocrinology, University Hospital Alexandrovska, Medical University, Sofia, Bulgaria
2Central clinical laboratory, University Hospital Alexandrovska, Medical University, Sofia, Bulgaria

Tóm tắt

The aim of the study was to investigate MCP-1 and fetuin A levels in women with PCOS and/or obesity before and after metformin treatment. In the study consisted of 59 patients. Anthropometric measurements and biochemical tests, including MCP-1 and fetuin A measurement, were performed. For patients that were diagnosed with insulin resistance and started metformin treatment all the laboratory tests and anthropometric measurements were repeated after 6 months. MCP-1 and fetuin A levels did not differ between patients with obesity with and without PCOS, between patients with PCOS with and without obesity, insulin resistance, arterial hypertension, dyslipidemia or menstrual disturbances. MCP-1 levels were significantly higher in patients with hyperandrogenemia than in patients without (456.3±141.1pmol/L vs. 372.5±108.5 pmol/L), while fetuin A levels were significantly higher in patients with metabolic syndrome (MetS) than in patients without MetS (278.5±41.1 mcg/ml vs. 240.0±42.0 mcg/ml). There was no significant change in MCP-1 and fetuin A levels after of metformin treatment. MCP- 1 levels are higher in patients with hyperandrogenemia and fetiun A levels are higher in patients with metabolic syndrome. MCP-1 and fetuin A levels do not change significantly after metformin treatment.

Tài liệu tham khảo

Ehrmann, D.A., et al., Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 1999. 22(1): p. 141–146

Legro, R.S., et al., Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab, 1999. 84(1): p. 165–169

Bjorntorp, P., The android woman—a risky condition. J Intern Med, 1996. 239(2): p. 105–110

Vrbikova, J., et al., Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod, 2003. 18(5): p. 980–984

Talbott, E., et al., Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol, 1995. 15(7): p. 821–826

Talbott, E., et al., Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol, 1998. 51(5): p. 415–422

Wild, R.A., P. Alaupovic, and I.J. Parker, Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol, 1992. 166(4): p. 1191–1196; discussion 1196–1997

Paradisi, G., et al., Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 2001. 103(10): p. 1410–1415

Lakhani, K., et al., Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet, 2000. 356(9236): p. 1166–1167

Davila-Roman, V.G., et al., Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol, 2002. 40(2): p. 271–277

Gerszten, R.E., et al., Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med, 2000. 136(2): p. 87–92

Aiello, R.J., et al., Monocyte chemoattractant protein- 1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 1999. 19(6): p. 1518–1525

Gu, L., et al., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998. 2(2): p. 275–281

Sartipy, P. and D.J. Loskutoff, Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA, 2003. 100(12): p. 7265–7270

Hu, W.H., et al., [Monocyte chemoattractant protein- 1 and its correlation with lipoprotein in polycystic ovary syndrome]. Beijing Da Xue Xue Bao, 2006. 38(5): p. 487–491

Gonzalez, F., et al., Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism, 2009. 58(7): p. 954–962

Glintborg, D., et al., Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf), 2009. 71(5): p. 652–658

Auberger, P., et al., Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell, 1989. 58(4): p. 631–640

Rauth, G., et al., The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem, 1992. 204(2): p. 523–529

Srinivas, P.R., et al., Serum alpha 2-HSglycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol, 1993. 7(11): p. 1445–1455

Mathews, S.T., et al., Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci, 1997. 61(16): p. 1583–1592

Stefan, N., et al., Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care, 2006. 29(4): p. 853–857

Mori, K., et al., Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care, 2006. 29(2): p. 468

Hennige, A.M., et al., Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One, 2008. 3(3): p. e1765

Stefan, N., et al., Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 2008. 57(10): p. 2762–2767

Roos, M., et al., Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept, 2009. 154(1–3): p. 39–43

Ix, J.H., et al., Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 2006. 113(14): p. 1760–1767

Weikert, C., et al., Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation, 2008. 118(24): p. 2555–2562

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41–47

Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 1995. 854: p. 1–452

Hu, W.H., J. Qiao, and M.Z. Li, [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases]. Zhonghua Yi Xue Za Zhi, 2007. 87(11): p. 721–724

Lindholm, A., et al., No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum Reprod, 2011. 26(6): p. 1478–1485

Zhu, J.P., et al., [Role of testosterone in tumor necrosis factor-alpha and monocyte chemotactic protein- 1 expression in mouse macrophage RAW264.7 and its molecular mechanism]. Zhonghua Yi Xue Za Zhi, 2009. 89(35): p. 2500–2503

Ishibashi, A., et al., Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb, 2010. 17(9): p. 925–933

Reinehr, T. and C.L. Roth, Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab, 2008. 93(11): p. 4479–4485

Xu, Y., et al., Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis, 2011. 216(1): p. 180–186

Mori, K., et al., Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism, 2008. 57(9): p. 1248–1252

Thông tin
Thông tin xuất bản

Central European Journal of Medicine

Tập 8

679-684

Thông tin tác giả